Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
This expanded approval is based on results from the pivotal FLOW phase 3b clinical trial, which demonstrated that once-weekly semaglutide led to a statistically significant 24% reduction in the risk of kidney disease progression, kidney failure, and cardiovascular death compared to placebo, when added to standard care
Current evidence suggests GLP 1 receptor agonists do not increase urinary tract infection risk
Ongoing support is another reason Utah residents trust TrimRx
From our FDA-registered pharmacy partnerships to our innovative telehealth platform, every element of our service is designed with your success in mind
US$ 28.99
US$ 26.48
US$ 29.25
US$ 20.76
US$ 22.30
US$ 28.69
US$ 25.86
US$ 23.42
US$ 21.55
US$ 29.12
US$ 28.71
